BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35993361)

  • 1. Axon guidance receptor ROBO3 modulates subtype identity and prognosis via AXL-associated inflammatory network in pancreatic cancer.
    Krebs N; Klein L; Wegwitz F; Espinet E; Maurer HC; Tu M; Penz F; Küffer S; Xu X; Bohnenberger H; Cameron S; Brunner M; Neesse A; Kishore U; Hessmann E; Trumpp A; Ströbel P; Brekken RA; Ellenrieder V; Singh SK
    JCI Insight; 2022 Aug; 7(16):. PubMed ID: 35993361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance.
    D'Errico G; Alonso-Nocelo M; Vallespinos M; Hermann PC; Alcalá S; García CP; Martin-Hijano L; Valle S; Earl J; Cassiano C; Lombardia L; Feliu J; Monti MC; Seufferlein T; García-Bermejo L; Martinelli P; Carrato A; Sainz B
    Oncogene; 2019 Jul; 38(27):5469-5485. PubMed ID: 30936462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma.
    Song X; Wang H; Logsdon CD; Rashid A; Fleming JB; Abbruzzese JL; Gomez HF; Evans DB; Wang H
    Cancer; 2011 Feb; 117(4):734-43. PubMed ID: 20922806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors in vivo.
    Moody G; Belmontes B; Masterman S; Wang W; King C; Murawsky C; Tsuruda T; Liu S; Radinsky R; Beltran PJ
    Int J Cancer; 2016 Sep; 139(6):1340-9. PubMed ID: 27170265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy.
    Leconet W; Larbouret C; Chardès T; Thomas G; Neiveyans M; Busson M; Jarlier M; Radosevic-Robin N; Pugnière M; Bernex F; Penault-Llorca F; Pasquet JM; Pèlegrin A; Robert B
    Oncogene; 2014 Nov; 33(47):5405-14. PubMed ID: 24240689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer.
    Cruz VH; Arner EN; Du W; Bremauntz AE; Brekken RA
    JCI Insight; 2019 Apr; 5(9):. PubMed ID: 30938713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer.
    Du W; Phinney NZ; Huang H; Wang Z; Westcott J; Toombs JE; Zhang Y; Beg MS; Wilkie TM; Lorens JB; Brekken RA
    Mol Cancer Res; 2021 Aug; 19(8):1412-1421. PubMed ID: 33811159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis.
    Kirane A; Ludwig KF; Sorrelle N; Haaland G; Sandal T; Ranaweera R; Toombs JE; Wang M; Dineen SP; Micklem D; Dellinger MT; Lorens JB; Brekken RA
    Cancer Res; 2015 Sep; 75(18):3699-705. PubMed ID: 26206560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic progenitor kinase 1 down-regulates the oncogenic receptor tyrosine kinase AXL in pancreatic cancer.
    Song X; Akasaka H; Wang H; Abbasgholizadeh R; Shin JH; Zang F; Chen J; Logsdon CD; Maitra A; Bean AJ; Wang H
    J Biol Chem; 2020 Feb; 295(8):2348-2358. PubMed ID: 31959629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer.
    Tu M; Klein L; Espinet E; Georgomanolis T; Wegwitz F; Li X; Urbach L; Danieli-Mackay A; Küffer S; Bojarczuk K; Mizi A; Günesdogan U; Chapuy B; Gu Z; Neesse A; Kishore U; Ströbel P; Hessmann E; Hahn SA; Trumpp A; Papantonis A; Ellenrieder V; Singh SK
    Nat Cancer; 2021 Nov; 2(11):1185-1203. PubMed ID: 35122059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rapid in vivo screen for pancreatic ductal adenocarcinoma therapeutics.
    Ocal O; Pashkov V; Kollipara RK; Zolghadri Y; Cruz VH; Hale MA; Heath BR; Artyukhin AB; Christie AL; Tsoulfas P; Lorens JB; Swift GH; Brekken RA; Wilkie TM
    Dis Model Mech; 2015 Oct; 8(10):1201-11. PubMed ID: 26438693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis.
    Bellomo G; Rainer C; Quaranta V; Astuti Y; Raymant M; Boyd E; Stafferton R; Campbell F; Ghaneh P; Halloran CM; Hammond DE; Morton JP; Palmer D; Vimalachandran D; Jones R; Mielgo A; Schmid MC
    Gut; 2022 Nov; 71(11):2284-2299. PubMed ID: 35022267
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.
    Antony J; Tan TZ; Kelly Z; Low J; Choolani M; Recchi C; Gabra H; Thiery JP; Huang RY
    Sci Signal; 2016 Oct; 9(448):ra97. PubMed ID: 27703030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
    Giles KM; Kalinowski FC; Candy PA; Epis MR; Zhang PM; Redfern AD; Stuart LM; Goodall GJ; Leedman PJ
    Mol Cancer Ther; 2013 Nov; 12(11):2541-58. PubMed ID: 24026012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis.
    Choi YJ; Kim JH; Rho JK; Kim JS; Choi CM; Kim WS; Son J; Lee JC
    Oncol Rep; 2017 Apr; 37(4):2201-2208. PubMed ID: 28260071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of
    Patil S; Steuber B; Kopp W; Kari V; Urbach L; Wang X; Küffer S; Bohnenberger H; Spyropoulou D; Zhang Z; Versemann L; Bösherz MS; Brunner M; Gaedcke J; Ströbel P; Zhang JS; Neesse A; Ellenrieder V; Singh SK; Johnsen SA; Hessmann E
    Cancer Res; 2020 Nov; 80(21):4620-4632. PubMed ID: 32907838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.
    Ruicci KM; Meens J; Plantinga P; Stecho W; Pinto N; Yoo J; Fung K; MacNeil D; Mymryk JS; Barrett JW; Howlett CJ; Boutros PC; Ailles L; Nichols AC
    J Exp Clin Cancer Res; 2020 Oct; 39(1):217. PubMed ID: 33059733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AXL Inhibitor TP-0903 Reduces Metastasis and Therapy Resistance in Pancreatic Cancer.
    Zhang Y; Arner EN; Rizvi A; Toombs JE; Huang H; Warner SL; Foulks JM; Brekken RA
    Mol Cancer Ther; 2022 Jan; 21(1):38-47. PubMed ID: 34675118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer.
    Ludwig KF; Du W; Sorrelle NB; Wnuk-Lipinska K; Topalovski M; Toombs JE; Cruz VH; Yabuuchi S; Rajeshkumar NV; Maitra A; Lorens JB; Brekken RA
    Cancer Res; 2018 Jan; 78(1):246-255. PubMed ID: 29180468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells.
    Cheng P; Phillips E; Kim SH; Taylor D; Hielscher T; Puccio L; Hjelmeland AB; Lichter P; Nakano I; Goidts V
    Stem Cell Reports; 2015 May; 4(5):899-913. PubMed ID: 25921812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.